If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
138
results.
Updated on
15/07/2026 [08:22:00]
Results 125 to 138 of 138
Absstract of: EP4748443A2
The invention pertains to a solid composition suitable for treating adult animals that suffer from brain-related disorders, brain-related decline or brain-related diseases, preferably suitable for treating adult animals that suffer from brain-related disorders, the composition containing (i) a uridine source, wherein the amount of the sum of all uridine sources, calculated on the basis of the weight of the molar equivalent of uridine monophosphate (UMP), is 0.3-15 g per 100 g dry weight of the composition, (ii) a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid, (iii) choline bitartrate, (iv) a buffering salt component, and (v) a milk protein source, wherein the milk protein source is a milk powder, and the buffering salt component containing at least one food approved salt, with a buffering capacity between pH 5 - 8, the buffering salt component preferably containing a mixture of food-approved salts, or a food-approved salt and its conjugated acid or base.
Absstract of: KR20260075695A
본 발명의 PI3K(Phosphoinositide 3-kinase) 억제제를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 약학적 조성물 및 이를 포함하는 파킨슨병의 예방 또는 치료용 약학적 제제와, 후보 약물의 파킨슨병 치료효과를 예측하는 방법에 의하여, 파킨슨병의 치료 및 최적의 치료효과를 갖는 후보 약물의 선정을 기대할 수 있다.
Absstract of: EP4748440A2
The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Accordingly, the present invention relates to compounds of formula (Id)whereinR1 is H and R2 is selected from one of the substituents (i) and (ii) below; orR1 is selected from one of the substituents (i) and (ii) below and R2 is H; orR1 and R2 are both represented by substituent (i) below; orR1 and R2 are both represented by substituent (ii) below; orR1 is substituent (i) and R2 is substituent (ii); orR1 is substituent (ii) and R2 is substituent (i);wherein * indicates the attachment point; andwherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.
Absstract of: EP4748385A1
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.
Absstract of: CZ2023279A3
The solution in question applies to the use of bis(phenylmethylene)cycloalkanones and their heterocyclic analogues with general formula I in human and veterinary medicine to treat the diseases caused by the presence of misfolded proteins in a cell, disbalance of protein homeostasis and proteotoxic stress, proteinopathy in general, particularly neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson disease (PD), Alzheimer disease (AD), Kennedy disease (KD), Huntington disease (HD), Creutzfeldt-Jakob disease (CJD), spinocerebellar ataxia (SCA), transthyretin familial amyloid polyneuropathy, dentatorubral–pallidoluysian atrophy, system- or organ-specific amyloidosis, as well as cystic fibrosis and diabetes.
Absstract of: US20260137640A1
0000 A compound of formula (I) or a pharmaceutically acceptable salt thereof is disclosed for use as a medicament. Further, the compound of formula (I) for use in the therapy of amyotrophic lateral sclerosis. Still further, a method of treating amyotrophic lateral sclerosis comprising administering to a subject in need thereof an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof is disclosed.
Absstract of: US20260139017A1
Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.
Absstract of: US20260137646A1
0000 Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.
Absstract of: AU2024364256A1
This disclosure relates to vectors, compositions, pharmaceutical compositions, and kits that provide for brain cell-specific expression of reprogramming genes such as the Yamanaka factors Oct4, Sox2, Klf4 and c-Myc (OSKM). Also provided are methods and uses comprising the same for treating Alzheimer' s disease and progeria through brain cell-specific expression of reprogramming genes such as OSKM.
Absstract of: US20260137692A1
0000 The present disclosure provides methods of diagnosing, characterizing, or treating diseases (e.g., Alzheimer's Disease) associated with phosphorylated tau proteins, including p-tau217 and p-tau243, in subjects in need thereof.
Absstract of: AU2026203338A1
Abstract This disclosure provides methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. This disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria- targeting peptidomimetic compound, such as (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol- 5-y l)pentyl)amino )-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof. Abstract
Absstract of: AU2024372247A1
The present invention relates to the field of medicine, and specifically relates to a crystal form A and crystal form B of 20(S)-protopanaxadiol, a preparation method therefor and the use thereof. The crystal form A and crystal form B provided in the present invention are different from the existing known crystal forms of 20(S)-protopanaxadiol, each have a distinct profile, can be perfectly reproduced, have good bulk density, fluidity and stability, and good characteristics in terms of fighting depression, anxiety and cognitive disorder, preventing and/or treating Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and treating diseases such as tumors or cardiovascular diseases, and have broad application prospects in the drug development of 20(S)-protopanaxadiol.
Nº publicación: EP4745142A1 20/05/2026
Applicant:
INCRELAND [CN]
Increland
Absstract of: EP4745142A1
Disclosed in the present invention are an aromatic compound, a pharmaceutical composition containing same, and a use thereof. The aromatic compound is a compound having formula (I), and can effectively degrade IRAK4 or otherwise inhibit IRAK4 activity. The compound and the pharmaceutical composition of the present invention have good prospects for application in IRAK4-mediated diseases including immune diseases, tumors, Alzheimer's disease, and fibrotic diseases, providing a new choice for clinically screening and/or preparing drugs for diseases associated with IRAK4 activity.
BOPI
Electronic site
